You've done the eccentric squats, you've put up with the shockwave sessions, and your knee still barks every time you land. What if a cheap, well-studied supplement could shorten that grind? A new randomized trial gives a tentative answer, and the details matter more than the headline.
The Short Version
Researchers tested creatine monohydrate (Creapure®) alongside a structured rehab program in athletes with patellar tendinopathy, better known as jumper's knee. By week 8, both the creatine and placebo groups had improved significantly. The difference showed up earlier. At week 4, only the creatine group had a statistically significant gain in the VISA-P, a questionnaire that scores pain and function. Only the creatine group also showed a significant gain in countermovement jump (CMJ) height.
That is promising, but it is not proof. More on that below.
What the Study Actually Did
The trial, led by Sánchez-Gómez and colleagues, was published in the Journal of the International Society of Sports Nutrition (2026). It was triple-blind and randomized. Twenty federated athletes (average age about 34) with patellar tendinopathy were split into a creatine group (n = 9) and a placebo group (n = 11).
Everyone followed the same rehab plan:
- Daily eccentric training plus stretching
- Extracorporeal shock wave therapy (ESWT) once every 10 days
- Manual therapy for the tendon and surrounding muscle
The supplement was taken at the end of each eccentric training session: three capsules of Creapure creatine monohydrate, or sucrose for placebo. Researchers assessed everyone at baseline, at 4 weeks, and at 8 weeks. They measured VISA-P, tendon thickness by ultrasound, body composition by bioimpedance, CMJ height, and 5-rep-max knee extension in the injured leg.
The Numbers That Got Attention
Pain and function (VISA-P): Scores rose significantly over time in both groups. At 8 weeks, the creatine group went from 60.6 to 78.0 points and the placebo group from 60.0 to 75.2. By week 8 the groups looked similar.
The difference was at the midpoint. The creatine group's VISA-P reached 70.2 at week 4, a significant improvement over baseline (p = 0.027). The abstract reports no comparable significant week-4 change for placebo.
Jump height: In the creatine group, CMJ rose from 34.3 cm to 36.8 cm by week 4 (p = 0.019), then to 37.6 cm at week 8 (p = 0.015). For athletes in jumping sports, that matters because the tendon is being rebuilt to tolerate exactly this kind of loading.
Tendon thickness and strength: Both groups improved over time on ultrasound tendon thickness and 5-RM leg extension. Creatine did not clearly add anything here, which suggests the rehab itself did the heavy lifting.
The Honest Caveats
Before you add creatine to your rehab plan, consider what the data can and cannot support.
- Tiny sample. With 20 athletes in total, and only 9 in the creatine arm, the results are fragile.
- The interaction only trended. The test of whether the groups changed differently over time gave p = 0.099 (partial η² = 0.126). That does not meet the usual 0.05 threshold. Saying "creatine worked at week 4 and placebo didn't" compares significance within each group, which is weaker evidence than a significant between-group difference.
- Return to play wasn't measured. The "faster return to play" idea is an inference from earlier pain relief and jump gains. Nobody timed a comeback to competition.
- Short follow-up. Eight weeks tells us nothing about re-injury or long-term tendon health.
- Mixed population. These were athletes averaging 33.7 years old, so the results may not transfer to adolescents or elite pros.
The authors themselves conclude only that creatine "could be considered" an ergogenic recovery aid. That is careful wording, and it should stay careful.
Who Might Care About This
The most relevant group is athletes in jumping or loading sports (volleyball, basketball, track and field, and similar) who are already doing a structured eccentric program for patellar tendinopathy and want an extra edge. Creatine is among the most studied supplements in sport, and it is inexpensive. For a healthy adult, the downside risk of trying it is generally considered low, though anyone with kidney issues or other medical conditions should check with a clinician first.
It is not a replacement for loading. In this trial, creatine was an add-on to a demanding program that included daily eccentric work, shockwave therapy, and manual treatment. Everyone improved in tendon thickness and strength largely because of that program.
Practical Takeaways: Dose and Timing
- Timing: In the study, creatine was taken right after each eccentric session. That is easy to copy, though the paper does not show that post-session timing beats other times of day.
- Dose: The abstract specifies three capsules of Creapure creatine monohydrate daily but does not state grams per capsule. Many creatine studies use roughly 3–5 g per day, but that is general background, not a finding from this paper. Check the full text or the product label.
- Form: The trial used creatine monohydrate, the most researched form, in a high-purity brand. There is no evidence here for fancier versions.
- Expectations: Think of it as a possible small accelerator in the first month, not a cure. By week 8, the placebo group had largely caught up on pain scores.
- Work with your clinician: Tendinopathy rehab should be guided by someone who can adjust load to your symptoms.
Bottom Line
This pilot-sized trial hints that creatine might speed up early pain relief and jump recovery in jumper's knee rehab. Because the between-group interaction only trended (p = 0.099) and the sample was 20 athletes, it is a reason to run bigger studies and not yet a reason to rewrite rehab protocols. If you already use creatine or are considering it, this gives you a plausible rationale. The eccentric work still has to get done.
Source: Sánchez-Gómez et al. "Could creatine supplementation combined with physical rehabilitation accelerate return to play in athletes with patellar tendinopathy?" J Int Soc Sports Nutr (2026). DOI: https://doi.org/10.1080/15502783.2026.2718846 | PubMed
